DOCSLIB.ORG

US 2015/0125441 A1 Wang Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
US 2015/0125441 A1 Wang Et Al US 2015O125441A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0125441 A1 Wang et al. (43) Pub. Date: May 7, 2015 (54) METHODS OF TREATING DEPRESSION AND Publication Classification PAIN (51) Int. Cl. (71) Applicant: NEW YORK UNIVERSITY, New A613 L/453 (2006.01) York, NY (US) A6II 45/06 (2006.01) A613 L/405 (2006.01) (72) Inventors: Jing Wang, New York, NY (US); (52) U.S. Cl. Edward Ziff, New York, NY (US) CPC ........... A6 IK3I/453 (2013.01); A61 K3I/4015 (2013.01); A61K 45/06 (2013.01) (73) Assignee: New York University, New York, NY (57) ABSTRACT (US) The present invention provides methods of treating and phar maceutical compositions useful for treating a mood disorder (21) Appl. No.: 14/401,202 or depressive symptoms associated with pain, inducing anal gesia and treating pain in a Subject by administering a phar (22) PCT Filed: May 24, 2013 maceutically effective amount of an agent capable of one or more of increasing GluA1 level, expression, concentration, or 86) PCT NO. PCT/US2013/042572 biological1ological activity,activitV. iincreasing calciumlci permeableble AMPA O. S371 (c)(1) amino-3-hydroxy-5-methylisoxazole-4-propionic acid) (2) Date: s Nov. 14, 2014 receptor (CPAR) level, expression, concentration, or biologi e - rs cal activity or potentiating a CPAR current. The agent may be an AMPA potentiator or ampakine. The agent may increase O O AMPA receptor currents by slowing the deactivation of open Related U.S. Application Data channels and may be, for instance, 2-pyrrolidinone, 4-2- (60) Provisional application No. 61/750,504, filed on Jan. (phenylsulfonylamino)ethylthio-2,6-difluorophenoxyaceta 9, 2013, provisional application No. 61/651,107, filed mide (PEPA) or LY451646. The agent may also be a protein, on May 24, 2012. RNA or DNA product. Patent Application Publication May 7, 2015 Sheet 1 of 11 US 201S/O125441 A1 FIG. 1A FIG. 1B FIG. 1C FIG. 1D Sham sham a A SN A SN 15 3.0 p<0.01 p<0.001 2.5 5 10 20 ss s 3 s 5 p<0.01 p<0.01 6. is 0 0.0 O s Baseline POD3 POD 14. Baseline POD 3 POD 14 POD 3 POD 14 POD 3 POD 14 gd FIG. 1E FIG. 1F FIG. 1 G FIG. 1H COe shell Core Shell O POD 3 POD14 POD3 POD14 Patent Application Publication May 7, 2015 Sheet 2 of 11 US 201S/O125441 A1 FIG. 2A FIG. 2B FIG. 2C FIG. 2D a fair pool 50pA 50pA n as 25mS 25ms 2 2 FIG. 2E FIG. 2F 31 NASPM NASPM 50pA 5OOA O fBaseline E. fBaseliné E. Sham SN Wm -70 mV Wm= -70 mV. p<0.001 FIG. 2 FIG. 2G 40 FIG. 2H400 EPSC arra N. BC 15 BC 12 30 N 300 N. 2 00 100 a. NAC Core =- Baseline NASPM Baseline NASPM Patent Application Publication May 7, 2015 Sheet 3 of 11 US 201S/O125441 A1 FIG. 3A -14 days 0 days 14 days FIG. 3C FIG. 3D FIG. 3E aSaline th s - s c 3 4. a NASPM as 9 S a B.S9 5O O S S as s s 2. S. 2 1 1 Es 9 S 3 85 O 12345678:10 c 2 .S. 9 C. o 5O O O Ol's SNI+ SNI+ time (bins of 3min) ge Saline NASPM Saline NASPM r c FIG. 3B FIG. 3F FIG. 3G FIG. 3H NASPM SS p40.01 p<0.05 Bc 1.7 Bc15 BC 12 U. K. £5 0.6 Stratin 38 04 0.4 is 86 86 SN + Sham + Sham + s" Sham SN. " SalineSN + NASPM Saline NASPM Patent Application Publication May 7, 2015 Sheet 4 of 11 US 201S/O125441 A1 FIG. 4A -14 days 0 days 14 days FIG. 4B F G. 4C 3 12 O O SN + SNI + SNI + SN + Saline 2-pyrrolidinone Saline 2-pyrrolidinone FIG. 4D FIG. 4E p<0.05 2-pyrrolidinone O BC 1.2 BC 1.2 Striatu : 2 O SN + SN + Saline 2-pyrrolidinone NAC Core Patent Application Publication May 7, 2015 Sheet 5 of 11 US 201S/O125441 A1 FIG. 5 -- naive -o- SN -A- sham Surgery -- SNI uninjured leg 2.0 1.5 1.0 0.5 0.0 ==s CD CY) N CO : S r : ? -- naive -o- SN -Al Sham -- SNI uninjured leg Patent Application Publication May 7, 2015 Sheet 6 of 11 US 201S/O125441 A1 FIG. 6A 150 100 5 O Sham SN baseline POD 14 POD56 FIG. 6C — — — naive Sham SN O1 8O 3% 0. 6 % baseline POD 2 POD 7 naive SN 2 sham Patent Application Publication May 7, 2015 Sheet 7 of 11 US 201S/O125441 A1 FIG. 7A - 15 s s O S SS S 5 O O 6hr 24 hr 48 hr >7 d paW incision Control 1.00 3 5 0.75 SD 92 5 0.50 CD 3 0.25 d 0.00 POD 1 POD 2 POD 7 paW incision Control Patent Application Publication May 7, 2015 Sheet 8 of 11 US 201S/O125441 A1 FIG. 8A Hippocampus FIG. 8B 1.5 1.0 aO.O Sham SN Sham SN FIG. 8C Cerebellum GluA1 ::::::::::::::::::::::::::: ---, ... : :------ Tubulin 8 8- :::::::::::::: z z FIG. 8D 1 15 10 0.5 0.0 Sham SN Sham SN Patent Application Publication May 7, 2015 Sheet 9 of 11 US 201S/O125441 A1 FIG. 9A sham 20ms "20ms FIG. 9B 50 O Sham V (mV) -75 - 25 50 75 -50 -100 O SN 100 V (mV) -75 -50 -25 25 50 75 -100 -200 FIG. 9C Rectification Index 15 1.0 0.5 0.0 Sham SN Patent Application Publication May 7, 2015 Sheet 10 of 11 US 201S/O125441 A1 FIG 10A FIG. 1 OB mechanical SuCrose preference hypersensitivity "p-0.05 p=0.5 0.9 o o 0.6 0.3 1 0.0 O Saline NASPM Saline NASPM FIG 10C loCOmotion -H Saline g 1500 - A - NASPM E 1000 2 p=0.3 E 500 8 O O (3min bins) 0 1 2 3 4 5 6 789 10 FIG. 1 OD NAC Shell Patent Application Publication May 7, 2015 Sheet 11 of 11 US 201S/O125441 A1 FIG. 1 1A S. mechanical allodynia 15 DMSO CX546 3 10 s is 5 2 s O S 10 mg/kg 5 mg/kg 2.5 mg/kg Cold allodynia 3 DMSO ge 2 CX546 ; O 8 1 O 10 mg/kg 5 mg/kg 2.5 mg/kg forced Swim test 250 3. 200 > DMSO Es 150 CX546 2 100 E 50 O DMSO CX546 (10mg/kg) US 2015/O125441 A1 May 7, 2015 METHODS OF TREATING DEPRESSION AND cology 2011; Tokita, et al., Pharmacol Biochem Behav 2011; PAN Koike, et al., Behav Brain Res 2011; 224: 107-11). 0005. A key glutamate signaling mechanism is the traf FIELD OF THE INVENTION ficking of C-amino-3-hydroxy-5-methyl-4-isoxazolepropi 0001. The present invention relates generally to treating onic acid (AMPA) receptors (Ziff, Neuron 2007:53: 627-33). mood disorders such as depression, particularly those asso AMPA receptors bind glutamate to conduct excitatory post ciated with or Subsequent to pain, Such as chronic pain, induc synaptic currents, and they are tetramers formed by varying ing analgesia and treating pain. combinations of four subunits, GluA1, 2, 3 and 4. GluA1 and GluA2 are the most abundant subunits in the NAc. GluA2 BACKGROUND OF THE INVENTION lacking AMPA receptors form in the NAc when GluA1 expression is increased, and they are permeable to calcium 0002 Pain is a major public health issue, affecting a third (Greger, et al Trends Neurosci 2007:30: 407-16). These cal of Americans. Loss of function as the result of pain costs our cium permeable AMPA receptors (CPARs) can regulate cal healthcare system over 300 billion dollars annually. Pain is a cium-dependent synaptic plasticity. While GluA2 subunits common morbidity after Surgery, and most pain patients Suf constitutively traffic to synapses, GluA1 trafficking is activ fer from depressed mood (Scott, et al., J. Bone Joint Surg Br ity-dependent and hence may respond to rewards (Barry, et al. 2010:92: 1253-8: Edwards, et al., Pain Res Manag 2009; 14: Curr Opin Neurobiol 2002; 12: 279-86) or pain. Thus, tightly 307-11 Dworkin, et al., Clin J. Pain 1991; 7: 79–94; Romano controlled GluA1 trafficking promotes the formation of et al., Psychol Bull 1985: 97: 18-34 and Rieckmann, et al., CPARs in the NAc and provides synaptic plasticity to regulate Psychother Pschother Psychosom 2006: 75: 353-61). Pain behaviors (Conrad, et al., Nature 2008; 454: 118-21). GluA1 induced depression impairs rehabilitation and worsens Surgi has been shown to modulate depressive symptoms. For cal outcome. example, GluA1 knockout mice display vulnerability to 0003. Depression is also a common and debilitating affec depression (Chourbaji, et al., FASEB J 2008: 22: 3129-34), tive feature of chronic pain (Dworkin, et al., ClinJ Pain 1991; and decreased GluA1 levels in the NAc have been reported in 7: 79-94; Miller, et al., J Pain 2009; 10: 619-627). Current rats that exhibit depressive behavior (Toth, et al., J. Neuro analgesics focus on sensory pain symptoms, but drugs such as chem 2008: 107: 522-32), whereas increased GluA1 levels NSAIDs and opioids have significant side effects. Thus, bet are found in the NAc with antidepressant treatments (Tan, et terunderstanding of the regulation of depression in pain states al. Exp Brain Res 2006: 170: 448-56). Studies in chronic pain will result in new treatments that focus on the depressive or postoperative pain, however, have not examined the role of symptoms of pain to improve daily function.
Load more

Recommended publications
  • Effects of Chronic Systemic Low-Impact Ampakine Treatment On
    Biomedicine & Pharmacotherapy 105 (2018) 540–544 Contents lists available at ScienceDirect Biomedicine & Pharmacotherapy journal homepage: www.elsevier.com/locate/biopha Effects of chronic systemic low-impact ampakine treatment on neurotrophin T expression in rat brain ⁎ Daniel P. Radin , Steven Johnson, Richard Purcell, Arnold S. Lippa RespireRx Pharmaceuticals, Inc., 126 Valley Road, Glen Rock, NJ, 07452, United States ARTICLE INFO ABSTRACT Keywords: Neurotrophin dysregulation has been implicated in a large number of neurodegenerative and neuropsychiatric Ampakine diseases. Unfortunately, neurotrophins cannot cross the blood brain barrier thus, novel means of up regulating BDNF their expression are greatly needed. It has been demonstrated previously that neurotrophins are up regulated in Cognitive enhancement response to increases in brain activity. Therefore, molecules that act as cognitive enhancers may provide a LTP clinical means of up regulating neurotrophin expression. Ampakines are a class of molecules that act as positive Neurotrophin allosteric modulators of AMPA-type glutamate receptors. Currently, they are being developed to prevent opioid- NGF induced respiratory depression without sacrificing the analgesic properties of the opioids. In addition, these molecules increase neuronal activity and have been shown to restore age-related deficits in LTP in aged rats. In the current study, we examined whether two different ampakines could increase levels of BDNF and NGF at doses that are active in behavioral measures of cognition. Results demonstrate that ampakines CX516 and CX691 induce differential increases in neurotrophins across several brain regions. Notable increases in NGF were ob- served in the dentate gyrus and piriform cortex while notable BDNF increases were observed in basolateral and lateral nuclei of the amygdala.
    [Show full text]
  • Performance Enhancement at the Cost of Potential Brain Plasticity: Neural Ramifications of Nootropic Drugs in the Healthy Developing Brain
    REVIEW ARTICLE published: 13 May 2014 SYSTEMS NEUROSCIENCE doi: 10.3389/fnsys.2014.00038 Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brain Kimberly R. Urban 1 and Wen-Jun Gao 2* 1 Department of Psychology, University of Delaware, Newark, DE, USA 2 Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA, USA Edited by: Cognitive enhancement is perhaps one of the most intriguing and controversial Mikhail Lebedev, Duke University, topics in neuroscience today. Currently, the main classes of drugs used as potential USA cognitive enhancers include psychostimulants (methylphenidate (MPH), amphetamine), Reviewed by: Kimberly Simpson, University of but wakefulness-promoting agents (modafinil) and glutamate activators (ampakine) are Mississippi Medical Center, USA also frequently used. Pharmacologically, substances that enhance the components Christopher R. Madan, University of of the memory/learning circuits—dopamine, glutamate (neuronal excitation), and/or Alberta, Canada norepinephrine—stand to improve brain function in healthy individuals beyond their *Correspondence: baseline functioning. In particular, non-medical use of prescription stimulants such as Wen-Jun Gao, Department of Neurobiology and Anatomy, Drexel MPH and illicit use of psychostimulants for cognitive enhancement have seen a recent University College of Medicine, rise among teens and young adults in schools and college campuses. However, this 2900 Queen Lane, Philadelphia, PA enhancement likely comes with a neuronal, as well as ethical, cost. Altering glutamate 19129, USA function via the use of psychostimulants may impair behavioral flexibility, leading to e-mail: [email protected] the development and/or potentiation of addictive behaviors. Furthermore, dopamine and norepinephrine do not display linear effects; instead, their modulation of cognitive and neuronal function maps on an inverted-U curve.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • General Anesthesia and Altered States of Arousal: a Systems Neuroscience Analysis
    General Anesthesia and Altered States of Arousal: A Systems Neuroscience Analysis The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Brown, Emery N., Patrick L. Purdon, and Christa J. Van Dort. “General Anesthesia and Altered States of Arousal: A Systems Neuroscience Analysis.” Annual Review of Neuroscience 34, no. 1 (July 21, 2011): 601–628. As Published http://dx.doi.org/10.1146/annurev-neuro-060909-153200 Publisher Annual Reviews Version Author's final manuscript Citable link http://hdl.handle.net/1721.1/86331 Terms of Use Creative Commons Attribution-Noncommercial-Share Alike Detailed Terms http://creativecommons.org/licenses/by-nc-sa/4.0/ NIH Public Access Author Manuscript Annu Rev Neurosci. Author manuscript; available in PMC 2012 July 06. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Annu Rev Neurosci. 2011 ; 34: 601–628. doi:10.1146/annurev-neuro-060909-153200. General Anesthesia and Altered States of Arousal: A Systems Neuroscience Analysis Emery N. Brown1,2,3, Patrick L. Purdon1,2, and Christa J. Van Dort1,2 Emery N. Brown: [email protected]; Patrick L. Purdon: [email protected]; Christa J. Van Dort: [email protected] 1Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114 2Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 3Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 Abstract Placing a patient in a state of general anesthesia is crucial for safely and humanely performing most surgical and many nonsurgical procedures.
    [Show full text]
  • The Role of Diallyl Thiosulfinate Associated with Nuciferine And
    Cai_Stesura Seveso 27/03/18 09:29 Pagina 59 DOI: 10.4081/aiua.2018.1.59 ORIGINAL PAPER The role of diallyl thiosulfinate associated with nuciferine and diosgenin in the treatment of premature ejaculation: A pilot study Tommaso Cai 1, Andrea Cocci 2, Giamartino Cito 2, Bruno Giammusso 3, Alessandro Zucchi 4, Francesco Chiancone 5, Maurizio Carrino 5, Francesco Mastroeni 6, Francesco Comerci 7, Giorgio Franco 8, Alessandro Palmieri 9 1 Department of Urology, Santa Chiara Regional Hospital, Trento, Italy; 2 Department of Urology, University of Florence, Florence, Italy; 3 Department of Andrology, Policlinico Morgagni, Catania, Italy; 4 Department of Urology, University of Perugia, Perugia, Italy; 5 Department of Urology, Cardarelli Hospital, Naples, Italy; 6 Department of Urology, Azienda Ospedaliera Papardo, Messina, Italy 7 Urologist, Bologna, Italy; 8 Department of Urology, Sapienza University of Rome, Rome, Italy; 9 Department of Urology, University of Naples, Federico II, Naples, Italy. Summary Objective: To assess the efficacy and safety with prevalence rates of 20-30%, probably affecting of an association of diallyl thiosulfinate with every man at some point in his life (2, 3). It may result nuciferine and diosgenin in the treatment of a group of patients in unsatisfactory sexual intercourse for both partners, suffering from premature ejaculation (PE), primary or second- decreasing sexual self-confidence and self-esteem and ary to erectile dysfunction (ED). resulting in an overall reduction of quality of life (QoL) Materials and methods: From July 2015 to October 2016, 143 (4). Lifelong PE occurs within 30-60 seconds after vagi- patients (mean age 25.3; range 18-39) affected by PE complet- ed the study and were finally analyzed in this phase I study.
    [Show full text]
  • Neuroenhancement in Healthy Adults, Part I: Pharmaceutical
    l Rese ca arc ni h li & C f B o i o l e Journal of a t h n Fond et al., J Clinic Res Bioeth 2015, 6:2 r i c u s o J DOI: 10.4172/2155-9627.1000213 ISSN: 2155-9627 Clinical Research & Bioethics Review Article Open Access Neuroenhancement in Healthy Adults, Part I: Pharmaceutical Cognitive Enhancement: A Systematic Review Fond G1,2*, Micoulaud-Franchi JA3, Macgregor A2, Richieri R3,4, Miot S5,6, Lopez R2, Abbar M7, Lancon C3 and Repantis D8 1Université Paris Est-Créteil, Psychiatry and Addiction Pole University Hospitals Henri Mondor, Inserm U955, Eq 15 Psychiatric Genetics, DHU Pe-psy, FondaMental Foundation, Scientific Cooperation Foundation Mental Health, National Network of Schizophrenia Expert Centers, F-94000, France 2Inserm 1061, University Psychiatry Service, University of Montpellier 1, CHU Montpellier F-34000, France 3POLE Academic Psychiatry, CHU Sainte-Marguerite, F-13274 Marseille, Cedex 09, France 4 Public Health Laboratory, Faculty of Medicine, EA 3279, F-13385 Marseille, Cedex 05, France 5Inserm U1061, Idiopathic Hypersomnia Narcolepsy National Reference Centre, Unit of sleep disorders, University of Montpellier 1, CHU Montpellier F-34000, Paris, France 6Inserm U952, CNRS UMR 7224, Pierre and Marie Curie University, F-75000, Paris, France 7CHU Carémeau, University of Nîmes, Nîmes, F-31000, France 8Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, 14050 Berlin, Germany *Corresponding author: Dr. Guillaume Fond, Pole de Psychiatrie, Hôpital A. Chenevier, 40 rue de Mesly, Créteil F-94010, France, Tel: (33)178682372; Fax: (33)178682381; E-mail: [email protected] Received date: January 06, 2015, Accepted date: February 23, 2015, Published date: February 28, 2015 Copyright: © 2015 Fond G, et al.
    [Show full text]
  • Ampakines Potentiate the Corticostriatal Pathway to Reduce Acute and Chronic Pain Fei Zeng1,2, Qiaosheng Zhang2, Yaling Liu2, Guanghao Sun2, Anna Li2, Robert S
    Zeng et al. Mol Brain (2021) 14:45 https://doi.org/10.1186/s13041-021-00757-y RESEARCH Open Access AMPAkines potentiate the corticostriatal pathway to reduce acute and chronic pain Fei Zeng1,2, Qiaosheng Zhang2, Yaling Liu2, Guanghao Sun2, Anna Li2, Robert S. Talay2 and Jing Wang2,3* Abstract The corticostriatal circuit plays an important role in the regulation of reward- and aversion-types of behaviors. Specif- cally, the projection from the prelimbic cortex (PL) to the nucleus accumbens (NAc) has been shown to regulate sensory and afective aspects of pain in a number of rodent models. Previous studies have shown that enhancement of glutamate signaling through the NAc by AMPAkines, a class of agents that specifcally potentiate the function of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, reduces acute and persistent pain. How- ever, it is not known whether postsynaptic potentiation of the NAc with these agents can achieve the full anti-noci- ceptive efects of PL activation. Here we compared the impact of AMPAkine treatment in the NAc with optogenetic activation of the PL on pain behaviors in rats. We found that not only does AMPAkine treatment partially reconstitute the PL inhibition of sensory withdrawals, it fully occludes the efect of the PL on reducing the aversive component of pain. These results indicate that the NAc is likely one of the key targets for the PL, especially in the regulation of pain aversion. Furthermore, our results lend support for neuromodulation or pharmacological activation of the corticostri- atal circuit as an important analgesic approach.
    [Show full text]
  • Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?
    Pharmaceuticals 2014, 7, 29-45; doi:10.3390/ph7010029 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction? Lucas R. Watterson 1,* and M. Foster Olive 1,2 1 Department of Psychology, Behavioral Neuroscience Area, Arizona State University, Tempe, AZ 85287, USA 2 Interdisciplinary Graduate Program in Neuroscience, Arizona State University, Tempe, AZ 85287, USA * Author to whom correspondence should be addressed; E-Mail:[email protected]; Tel.: +1-480-965-2573. Received: 28 October 2013; in revised form: 13 December 2013 / Accepted: 24 December 2013 / Published: 30 December 2013 Abstract: Positive allosteric modulators (PAMs) of α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptors are a diverse class of compounds that increase fast excitatory transmission in the brain. AMPA PAMs have been shown to facilitate long-term potentiation, strengthen communication between various cortical and subcortical regions, and some of these compounds increase the production and release of brain-derived neurotrophic factor (BDNF) in an activity-dependent manner. Through these mechanisms, AMPA PAMs have shown promise as broad spectrum pharmacotherapeutics in preclinical and clinical studies for various neurodegenerative and psychiatric disorders. In recent years, a small collection of preclinical animal studies has also shown that AMPA PAMs may have potential as pharmacotherapeutic adjuncts to extinction-based or cue-exposure therapies for the treatment of drug addiction. The present paper will review this preclinical literature, discuss novel data collected in our laboratory, and recommend future research directions for the possible development of AMPA PAMs as anti-addiction medications.
    [Show full text]
  • Preferred Drug List 4-Tier
    Preferred Drug List 4-Tier 21NVHPN13628 Four-Tier Base Drug Benefit Guide Introduction As a member of a health plan that includes outpatient prescription drug coverage, you have access to a wide range of effective and affordable medications. The health plan utilizes a Preferred Drug List (PDL) (also known as a drug formulary) as a tool to guide providers to prescribe clinically sound yet cost-effective drugs. This list was established to give you access to the prescription drugs you need at a reasonable cost. Your out- of-pocket prescription cost is lower when you use preferred medications. Please refer to your Prescription Drug Benefit Rider or Evidence of Coverage for specific pharmacy benefit information. The PDL is a list of FDA-approved generic and brand name medications recommended for use by your health plan. The list is developed and maintained by a Pharmacy and Therapeutics (P&T) Committee comprised of actively practicing primary care and specialty physicians, pharmacists and other healthcare professionals. Patient needs, scientific data, drug effectiveness, availability of drug alternatives currently on the PDL and cost are all considerations in selecting "preferred" medications. Due to the number of drugs on the market and the continuous introduction of new drugs, the PDL is a dynamic and routinely updated document screened regularly to ensure that it remains a clinically sound tool for our providers. Reading the Drug Benefit Guide Benefits for Covered Drugs obtained at a Designated Plan Pharmacy are payable according to the applicable benefit tiers described below, subject to your obtaining any required Prior Authorization or meeting any applicable Step Therapy requirement.
    [Show full text]
  • Optogenetic Stimulation of Prefrontal Glutamatergic Neurons Enhances Recognition Memory
    4930 • The Journal of Neuroscience, May 4, 2016 • 36(18):4930–4939 Behavioral/Cognitive Optogenetic Stimulation of Prefrontal Glutamatergic Neurons Enhances Recognition Memory Abigail Benn, Gareth R. I. Barker, Sarah A. Stuart, XEva v. L. Roloff, XAnja G. Teschemacher, E. Clea Warburton, and Emma S. J. Robinson School of Physiology, Pharmacology, and Neuroscience, Faculty of Biomedical Sciences, University of Bristol, Bristol BS8 1TD, United Kingdom Finding effective cognitive enhancers is a major health challenge; however, modulating glutamatergic neurotransmission has the poten- tial to enhance performance in recognition memory tasks. Previous studies using glutamate receptor antagonists have revealed that the medial prefrontal cortex (mPFC) plays a central role in associative recognition memory. The present study investigates short-term recognition memory using optogenetics to target glutamatergic neurons within the rodent mPFC specifically. Selective stimulation of glutamatergic neurons during the online maintenance of information enhanced associative recognition memory in normal animals. This cognitive enhancing effect was replicated by local infusions of the AMPAkine CX516, but not CX546, which differ in their effects on EPSPs. This suggests that enhancing the amplitude, but not the duration, of excitatory synaptic currents improves memory performance. Increasing glutamate release through infusions of the mGluR7 presynaptic receptor antagonist MMPIP had no effect on performance. Key words: AMPAkine; optogenetics; prefrontal cortex; rat; recognition memory Significance Statement These results provide new mechanistic information that could guide the targeting of future cognitive enhancers. Our work suggests that improved associative-recognition memory can be achieved by enhancing endogenous glutamatergic neuronal ac- tivity selectively using an optogenetic approach. We build on these observations to recapitulate this effect using drug treatments thatenhancetheamplitudeofEPSPs;however,drugsthatalterthedurationoftheEPSPorincreaseglutamatereleaselackefficacy.
    [Show full text]
  • Enhancement of Ampakine-Induced
    (19) & (11) EP 1 715 863 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/445 (2006.01) A61K 31/40 (2006.01) 09.05.2012 Bulletin 2012/19 A61K 31/4525 (2006.01) A61K 45/06 (2006.01) (21) Application number: 05712023.0 (86) International application number: PCT/US2005/002372 (22) Date of filing: 26.01.2005 (87) International publication number: WO 2005/072345 (11.08.2005 Gazette 2005/32) (54) ENHANCEMENT OF AMPAKINE-INDUCED FACILITATION OF SYNAPTIC RESPONSES BY CHOLINESTERASE INHIBITORS VERBESSERUNG DER DURCH AMPAKINE INDUZIERTEN ERLEICHTERUNG VON SYNAPTISCHEN REAKTIONEN DURCH CHOLINESTERASE-INHIBITOREN RENFORCEMENT DE LA FACILITATION INDUITE PAR AMPAKINE DES REPONSES SYNAPTIQUES PAR LES INHIBITEURS DE LA CHOLINESTERASE (84) Designated Contracting States: (74) Representative: Baldock, Sharon Claire AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Boult Wade Tennant HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR Verulam Gardens 70 Gray’s Inn Road (30) Priority: 26.01.2004 US 539422 P London WC1X 8BT (GB) (43) Date of publication of application: (56) References cited: 02.11.2006 Bulletin 2006/44 EP-A- 1 203 584 US-A- 5 747 492 US-B2- 6 689 795 (73) Proprietors: • CORTEX PHARMACEUTICALS, INC. • JOHNSON STEVEN A ET AL: "Randomized, Irvine, CA 92618 (US) double-blind, placebo-controlled international • The Regents of The University of California clinical trial of the Ampakine CX516 in elderly Oakland, CA 94607-5200 (US) participants with mild cognitive impairment.
    [Show full text]
  • Mechanisms of Addiction
    Mechanisms of Addiction Prof David Nutt, FMedSci Centre for Neuropsychopharmacology, Division of Brain Sciences, Burlington Danes Building, Imperial College London, London W12 0NN, UK. [email protected] www.tocris.com What is addiction? Although the term addiction is controversial because it can be stigmatizing and divisive, we use it here as a useful shorthand for the processes by which people become dependent on the use of drugs, or activities such as gambling, to the point where it distorts and even takes over their lives. The key feature of drug addiction is the inability to stop using the drug despite clear evidence of harm; the drug becomes progressively more important, dominating life at the expense of family, friends and work. Not all those who use drugs become addicted and factors that predispose to addiction include the class of drug, family history of addiction and propensity to withdrawal reactions and craving. Using drugs to deal with psychiatric problems is particularly likely to lead to addiction. Brain Circuits Associated with Addiction Classes of Addictive Drugs Products available from Tocris Stimulants Stimulants are drugs that act by releasing dopamine and, D Cocaine, (D)-Amphetamine sulfate, 3 Morphine, Mephedrone, in some cases, blocking its reuptake. This class includes Threo-methylphenidate D cocaine (and crack), amphetamine and its derivatives such 1,5 MAO as metamphetamine (crystal meth) and methylphenidate, + ATP (R)-(-)-Deprenyl, Moclobemide DA and some cathinones, such as mephedrone. Their actions DAT PFC AC are dependent on speed of brain penetration, with smoking cAMP PKA GBR 12909, Tetrabenazine, Reserpine, MAO VMAT and iv injection the most addictive routes, but are largely – (±)-MDMA CREB Dopamine D and D ACG unaffected by dopamine receptor antagonists.
    [Show full text]